Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
about
Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Combined kinase inhibitors of ...... triple-negative breast cancer.
@en
Combined kinase inhibitors of ...... triple-negative breast cancer.
@nl
type
label
Combined kinase inhibitors of ...... triple-negative breast cancer.
@en
Combined kinase inhibitors of ...... triple-negative breast cancer.
@nl
prefLabel
Combined kinase inhibitors of ...... triple-negative breast cancer.
@en
Combined kinase inhibitors of ...... triple-negative breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Combined kinase inhibitors of ...... triple-negative breast cancer
@en
P2093
Allison Deal
Amanda E D Van Swearingen
Brian T Golitz
Carey K Anders
Charlene Santos
Gary L Johnson
Joel S Parker
Louisa Mounsey
Maria J Sambade
Marni B Siegel
P2860
P304
P356
10.1093/NEUONC/NOX052
P577
2017-10-01T00:00:00Z